Small molecule inhibitors of KRAS G12C mutant
The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W 1 , W 2 , Y, Z, M, L, C y , C z , R 1 , R 2 , R 3 , R 4 , R 2a , R y , R z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
1. A compound selected from the group consisting of:
2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-18,21-difluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-ethenopyrido[4,3-f]pyrimidol[1,6,h][1,8,10]benzoxadiazacyclotridecin-4-one;
(5aS a ,17aR a )-20-chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-dihydro-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido [1,6-g][1,4,7,9]benzodioxadiazacyclododecin-4-one;
(5aS a ,17aR a )-20-Chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-di[( 2 H)hydro](11,12- 2 H 2 )-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6-g][1,4,7,9]benzodioxadiazacyclododecin-4-one;
(5aR a ,18aR a )-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,18,21-tetrafluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1,8,10]benzoxadiazacyclotridecin-4-one;
(5aR a ,18aR a )-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,17,18,21-pentafluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1,8,10]benzoxadiazacyclotridecin-4-one;
(5aR a ,18aR a )-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,15,18,21-pentafluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1,8,10]benzoxadiazacyclotridecin-4-one;
(5aR a ,18aR a )-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,16,18,21-pentafluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1,8,10]benzoxadiazacyclotridecin-4-one;
(5 aS a ,17aR a )-20-chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-16,17-difluoro-6-(propan-2-yl)-11,12-di[( 2 H)hydro](11,12- 2 H 2 )-4H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6-g][1,4,7,9]benzodioxadiazacyclododecin-4-one;
2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,17,18,21-pentafluoro-6-(propan-2-yl)-10,11,12,13-tetrahydro-4H-1,19-(ethanediylidene)dipyrimido[4,5-f1′,6′-h][1,8,10]benzoxadiazacyclotridecin-4-one;
21-chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-12,12,18-trifluoro-6-(propan-2-yl)-12,13-dihydro-4H,11H−1,19-(ethanediylidene)pyrido[4,3-f]pyrimido[1,6-h][1,5,8,10]benzodioxadiazacyclotridecin-4-one;
20-chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-17-fluoro-6-(propan-2-yl)-11,12-dihydro-4H,10H-1,18-(ethanediylidene)pyrido[4,3-e]pyrimido[1,6-g][1,7,9]benzoxadiazacyclododecin-4-one; or
a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising the compound of claim 3 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. A compound having the formula:
6. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.
7. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound of claim 7 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. A compound having the formula:
10. A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier.
11. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising the compound of claim 11 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13. A compound having the formula:
14. A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.
15. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising the compound of claim 15 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A compound having the formula:
18. A pharmaceutical composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.
19. A compound having the formula:
or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising the compound of claim 19 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. A compound having the formula:
22. A pharmaceutical composition comprising the compound of claim 21 and a pharmaceutically acceptable carrier.